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Abstract
Introduction: Headache is one of the most frequent neurologic manifestations in COVID-19. We aimed to analyze
which symptoms and laboratory abnormalities were associated with the presence of headache and to evaluate if
patients with headache had a higher adjusted in-hospital risk of mortality.
Methods: Retrospective cohort study. We included all consecutive patients admitted to the Hospital with
confirmed SARS-CoV-2 infection between March 8th and April 11th, 2020. We collected demographic data, clinical
variables and laboratory abnormalities. We used multivariate regression analysis.
Results: During the study period, 576 patients were included, aged 67.2 (SD: 14.7), and 250/576 (43.3%) being
female. Presence of headache was described by 137 (23.7%) patients. The all-cause in-hospital mortality rate was
127/576 (20.0%). In the multivariate analysis, patients with headache had a lower risk of mortality (OR: 0.39, 95% CI:
0.17–0.88, p = 0.007). After adjusting for multiple comparisons in a multivariate analysis, variables that were
independently associated with a higher odds of having headache in COVID-19 patients were anosmia, myalgia,
female sex and fever; variables that were associated with a lower odds of having headache were younger age,
lower score on modified Rankin scale, and, regarding laboratory variables on admission, increased C-reactive
protein, abnormal platelet values, lymphopenia and increased D-dimer.
Conclusion: Headache is a frequent symptom in COVID-19 patients and its presence is an independent predictor
of lower risk of mortality in COVID-19 hospitalized patients.
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Background
Coronavirus disease 2019 (COVID-19) is caused by se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1]. The severity of symptomatic cases varies
from mild to critical. In the case of Spain, analyzing data
from more than 250,000 infected patients, 38.4% of pa-
tients needed hospitalization, 3.9% were admitted to the
Intensive Care Unit (ICU) and 8.2% expired [2]. Several
factors may affect the prognosis, including male sex,
older age, hypertension, diabetes, smoking, cardiovascu-
lar disorders, chronic neurological disorders, and pul-
monary diseases, among others [3, 4]. Regarding clinical
manifestations, fever and dyspnea have been associated
with severity and mortality of COVID-19 as well [3].
Headache is one of the most frequent neurologic man-
ifestations in COVID-19. The reported frequency of
headache in a recent meta-analysis was 12% of patients
[5], ranging from 6.5% [6] to 70.3% [7] depending on the
studies, with most of the studies reporting a frequency
within 10–30% of patients [8, 9]. Headache might be
caused by the release of cytokines, endothelial damage
and macrophage activation; or it could be related to the
inflammation of lymphatic structures, as the lymphatic
organs located in the naso- and oropharynx around the
Waldeyer’s ring [10, 11]. The real causes of headache in
COVID-19 are still uncertain. Whether the presence of
headache reflects a more severe course of COVID-19, or
if it is associated with a better prognosis because of a
more efficient host response against the virus is also
unclear.
In the present study, we aimed to evaluate whether
prognosis of hospitalized patients with COVID-19, eval-
uated by in-hospital all-cause mortality rate, differed in
patients with headache compared to those without head-
ache. As a secondary objective, we assessed which vari-
ables were associated with the presence of headache in
COVID-19 patients. We hypothesized that the presence
of headache might be related to a different COVID-19
presentation in terms of severity and inflammatory
response.
Methods
We performed an observational analytic study with a
retrospective cohort design. The study was done in a ter-
tiary academic public hospital (Clinic University Hospital
of Valladolid, Valladolid, Spain) with a reference popula-
tion of 280,000 patients. The study was performed ac-
cording to the strengthening the reporting of
observational studies in epidemiology (STROBE) state-
ment [12]. The study was designed and data were ana-
lyzed by the authors. All co-authors contributed to the
collection, analysis and interpretation of data, as well as
to the reviewing and approving of the final version of
the manuscript.
We included all consecutive patients that were admit-
ted to the Hospital with a confirmed SARS-CoV-2 infec-
tion diagnosis between March 8th and April 11th, 2020.
The diagnosis was set, according to the World Health
Organization (WHO) protocols [13], by real-time reverse
transcriptase polymerase -chain reaction (RT-PCR) assay
(LightMix Modular SARS-CoV (COVID19) E-gene and
LightMix Modular SARS-CoV-2 RdRP, Roche Diagnos-
tics) from oropharyngeal swab, sputum sample, or lower
respiratory tract sample; or by the presence of anti-
SARS-CoV-2 IgM + IgA antibodies (COVID-19 ELISA
IgM + IgA, Vircell, S.L. Granada, Spain) in patients with
clinical symptoms. Patients were excluded if the
hospitalization was not done from the emergency de-
partment (ED) or if the patients’ records were not
accessible.
Data sources
Data were collected from electronic medical records. The
information was gathered from primary care records,
emergency room records, and discharge reports. Data
were extracted between April 21st and May 1st, and the
minimum follow-up time after admission was 20 days
(ranging from 20 to 61 days) and the last patients were
contacted on May 25th. Details of the study have been de-
scribed elsewhere [4]. In those patients in which the pres-
ence of headache was not described, a trained neurologist
contacted the patient or their relatives by phone and spe-
cifically inquired about it. All patients were evaluated after
the resolution of all symptoms COVID-19 or after 20 days
of COVID-19 symptoms. The detailed description of the
headache screening process is available in supplementary
materials. We analyzed the presence of any new onset
headache developed in temporal relation to the onset of
the viral infection, or any headache described as different
to the pre-existing headache. During the hospitalization,
patients were treated according to the national standard
of care [14, 15].
Study objectives
The primary objective was to evaluate if hospitalized
COVID-19 patients with headache had a higher risk of
all-cause in-hospital mortality compared to those with-
out headache. The secondary objective was to analyze
which variables were independently associated with the
presence of headache in COVID-19 patients.
Variables
Baseline variables included demographic data, presence
of comorbidities, and details about treatment for any
chronic diseases. Demographic data included age, sex
and baseline performance status according to the modi-
fied Rankin scale (mRS) [16]. The evaluated comorbidi-
ties included hypertension, diabetes, smoking habits,
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cardiovascular diseases, pulmonary diseases, cancer, an
immunocompromised state, and chronic neurological
diseases [4], and we also assessed whether patients had a
prior history of headache. We analyzed whether patients
were previously treated with angiotensin-converting en-
zyme inhibitors (ACEis), angiotensin II receptor blockers
(ARBs), non-steroidal anti-inflammatory drugs (NSAI
Ds), corticosteroids, or other neuropharmacological
therapies.
We evaluated the presence of COVID-19 general
symptoms, including anosmia, arthralgia, asthenia, chest
pain, cough, cutaneous rash, diarrhea, dyspnea, expec-
toration, fever, lightheadedness, myalgia, odynophagia,
rhinorrhea, syncope, vomiting and weakness. Regarding
laboratory parameters, we described both the first deter-
mination and the worst value during the hospitalization
period, and we also analyzed the frequency of abnormal
values. The studied parameters were leukocytes (cell
count × 109/L, reference value (RV): 4–10), lymphocytes
(count × 109/L, RV: 0.9–5.2), platelets (count × 109/L,
RV: 150–400), hemoglobin (g/dL, RV: 12–16), inter-
national normalized ratio (INR; RV: 0.8–1.3), D-dimer
(ng/dL, RV: < 500), lactate dehydrogenase (LDH; U/L,
RV: 135–250), creatine kinase (U/L, RV: 20–170), glom-
erular filtration rate (GFR) corrected by body area (ml/
min/1.73m2, RV > 90), C-reactive protein (CRP; mg/L,
RV: 1–5), procalcitonin (PCT; ng/mL, RV < 5),
interleukin-6 (IL-6; pg/mL, RV < 5.9), and ferritin (ng/
mL, RV: 15–150). We described whether chest imaging
was abnormal by using either X-ray or computerized
tomography scan. We analyzed the all-cause in-hospital
mortality.
Ethics
The study protocol was approved by the Institutional
Review Board of the East Valladolid health area (PI-20-
1751). Because of the risk of contagion, the retrospective
nature of the study and the urgent need to obtain data,
written informed consent was waived. However, all pa-
tients were informed about the nature of the study and
were invited to participate when contacted by phone. In
those patients that were personally interviewed, written
informed consent was obtained. Personal information
about patients was codified before entry into the data-
base, and the identities of patients were anonymous. The
study was done in accordance with the principles of the
Declaration of Helsinki [17].
Statistical analysis
We describe qualitative and ordinal variables as frequen-
cies and percentages, respectively, and quantitative con-
tinuous variables as means and standard deviations (SD)
if the distribution was normal or medians and interquar-
tile ranges (IQR) otherwise. We assessed normality by
using the Kolmogorov-Smirnov test. We used two-tailed
chi-square tests or Fisher’s exact tests for hypothesis
testing of qualitative variables, and an independent sam-
ples Student’s t-test or a median test for hypothesis test-
ing of quantitative, continuous variables if the
distribution was normal or not normal, respectively. The
level of significance was set to 0.05, adjusting for mul-
tiple comparisons by using the Bonferroni method. We
managed missing data by using complete case analysis.
For the primary objective, we employed a univariate lo-
gistic regression analysis to determine which variables
were associated with higher odds of mortality, including
the presence of headache. Those variables with p-values
less than or equal to 0.2 were included in a subsequent
multivariate logistic regression analysis. We present the
odds ratio (OR) and the 95% confidence interval (CI).
To analyze which variables were associated with the
presence of headache, we employed a univariate regres-
sion analysis. We were more stringent due to the high
number of studied variables, so we further studied only
those variables that had a p-value less than or equal to 0.1
in the univariate regression model. The multivariate logis-
tic regression analysis was performed following the Wald
procedure and a backwards strategy. We adjusted for mul-
tiple comparisons by using the False Discovery Rate (FDR)
with Benjamini-Hochberg procedure [18]. Statistical sig-
nificance was achieved if the p-value was < 0.05 after cor-
recting for multiple comparisons. We analyzed
multicollinearity by using the variance inflation factor
(VIF). We considered multicollinearity as critical when
VIF was > 5. We did not estimate the sample size a priori
and the analysis proceeded on the available data. The ana-
lysis of the study was preplanned. Statistical analysis was
performed with SPSS v.26 (IBM Corp. Armonk, NY).
Results
During the study period, 580 consecutive patients ful-
filled inclusion criteria. Three patients were excluded be-
cause they were not admitted from the ED and one
because there was no available information. Diagnosis
was confirmed by RT-PCR in 546/576 (94.8%) of cases
and/or serology in 175/576 (30.4%). The mean age was
67.2 (SD: 14.7), and 250/576 (43.3%) were female.
Presence of headache was described by 137 (23.7%) pa-
tients. The headache was already present at the moment
of the ED consultation in 124/137 (90.5%) patients. The
headache was the first symptom in 27/104 (26.0%) pa-
tients and was present within 24 h in 40/104 (38.5%) pa-
tients, within 48 h in 65/104 (62.5%) patients and within
72 h in 77/104 (74.0%) patients. Female sex and prior
history of headache were more frequent in patients with
headache, while mean Rankin scale, and frequency of
hypertension, smoking habits, cardiological disorders
and chronic neurological disorders were more frequent
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in patients without headache after adjusting for multiple
comparisons (p = 0.0029). Demographic data, comorbidi-
ties, and data about the chronic treatment of the full
sample and the group of patients with and without head-
ache are available in Table 1. Prior episodes of headache
associated with systemic viral infections were described
by 50/106 (47.2%) of patients with headache, and the
present episode was described to be similar to the
former in 23/50 (46.0%) of the cases. During the
hospitalization, 55 (40.1%) patients with headache re-
ceived systemic steroids compared to 245 (55.9%) pa-
tients without headache (p = 0.002). All-cause in-hospital
mortality rate was 127/576 (20.0%) in the whole sample
and 8/137 (5.8%) in headache patients.
Primary objective: mortality
In the univariate regression analysis, baseline disability, age,
hypertension, diabetes, smoking habit, cardiological disor-
ders, cancer, and chronic neurological disorders were asso-
ciated with higher odds of death, while presence of
headache and time between onset of symptoms and ED
visit were associated with a lower odds of death. In the
multivariate regression analysis, baseline disability (OR:
4.10, 95% CI: 2.09–8.05; p-value: < 0.001, FDR-corrected
p-value: < 0.001), age (OR: 1.06, 95% CI 1.03–1.08;
p-value: < 0.001, FDR-corrected p-value: < 0.001) and
headache (OR: 0.39, 95% CI: 0.17–0.88; p-value: 0.028, FDR-
corrected p-value: 0.007) remained statistically significant. Full
results of the regression analysis are presented in Table 2.
Associated symptoms and laboratory abnormalities
Anosmia, arthralgia, cough, lightheadedness, and myalgia
were statistically more frequent in patients with headache
after adjusting for multiple comparisons (p = 0.0029). The
frequencies of associated symptoms in the full sample and
comparisons between patients with and without headache
are presented in Table 3. When comparing patients with
and without headache, we observed significant differences
in median values of laboratory parameters on admission
for CRP, PCT, and D-dimer (p < 0.0025 for all after adjust-
ing for multiple comparisons). Of the worst experienced
laboratory values during hospitalization, median values
were significantly different for leukocytes, lymphocytes,
LDH, CRP, PCT, ferritin, IL-6, D-dimer and INR for those
with and without headache. Table 4 shows the median
values of laboratory parameters.
Variables associated with the presence of headache
In the univariate regression analysis, 56 different vari-
ables were included in the model, of which 39 had a p-
value < 0.1 (supplementary Table 1). We included those
39 variables in a multivariate regression analysis, and 11
variables were statistically significant. After FDR adjust-
ments, 10 variables remained statistically significant. The
variables that were independently associated with a
higher odds of headache in hospitalized COVID-19 pa-
tients were anosmia, myalgia, female sex, and fever;
while the variables that were independently associated
with a lower odds of having headache were age, modified








Female sex 250 (43.3%) 80 (58.4%) 170 (38.7%) < 0.001
Age (years) 67.2 (SD: 14.7) 59.25 (SD: 12.4) 69.6 (SD: 14.5) < 0.001
Modified Rankin scale (mean) 0.61 (SD: 1.12) 0.15 (SD: 0.5) 0.75 (SD: 1.2) < 0.001
Hypertension 300 (52.1%) 52 (38%) 248 (56.5%) < 0.001
Diabetes 113 (19.6%) 20 (14.6%) 93 (21.2%) 0.090
Smoking 118 (20.5%) 20 (14.6%) 98 (22.3%) 0.050
Cardiological disorders 154 (26.7%) 19 (13.9%) 135 (30.8%) < 0.001
Pulmonary disorders 145 (25.2%) 33 (24.1%) 112 (25.5%) 0.737
Cancer 94 (16.3%) 18 (13.1%) 76 (17.3%) 0.249
Immuno-suppression 24 (4.2%) 4 (2.9%) 20 (4.6%) 0.409
Chronic neurological disorders 105 (18.3%) 13 (9.5%) 92 (2%) 0.002
Prior history of headache 32 (5.6%) 15 (10.9%) 17 (3.9%) 0.002
ACEis /ARBs 215 (37.3%) 42 (30.7%) 173 (39.4%) 0.064
NSAIDs 75 (13%) 12 (8.8%) 66 (14.4%) 0.090
Corticosteroids 35 (6.1%) 7 (5.1%) 28 (6.4%) 0.587
Neuropharmacological treatment 203 (35.2%) 42 (30.7%) 161 (36.7%) 0.198
Time symptoms-ED (days) 7.34 (SD: 6.16) 8.51 (SD: 5.90) 6.98 (SD: 6.21) 0.011
ACEis angiotensin-converting enzyme inhibitors, ARBs angiotensin II receptor blockers, NSAIDs non-steroidal anti-inflammatory drugs, ED Emergency department. In
bold, variables that were statistically significant after adjusting for multiple comparisons (threshold p < 0.0029)
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Rankin scale, increased CRP on admission, abnormal
platelet value on admission, lymphopenia on admission,
and increased D-dimer on admission. The VIF was less
than or equal to 1.131 in all cases. Full results of the
multivariate regression analysis are shown in Table 5
and Fig. 1.
Discussion
In this study we analyzed which variables were associ-
ated with the presence of headache in COVID-19 pa-
tients and whether patients with headache had a worse
prognosis, assessed by the risk of all-cause, in-hospital
mortality. For this, we studied a large cohort of hospital-
ized patients with confirmed COVID-19, and we
systematically interrogated them about the presence of
headache.
SARS-CoV-2 causes respiratory symptoms in most pa-
tients. However, neurological symptoms are among the
most frequent extrapulmonary symptoms [8, 9]. After an
incubation period of 2–14 days [1], most patients present
general symptoms for 1–3 weeks [19]. Patients with
comorbidities are particularly vulnerable to the virus [4,
20], and there are several risk factors that have been asso-
ciated with a worse prognosis [3, 21, 22]. The prompt
diagnosis, isolation and treatment of patients is crucial
[23]. Every clinician should be prepared for facing the
virus, as the pandemic has extended worldwide causing
hundreds of thousands of deaths and millions of cases [2].
Headache is a frequent symptom of COVID-19. It was
present in almost a quarter of our sample. This fre-
quency was higher than in other previously reported
series, which described a 6–15% prevalence [5, 6, 8, 9].
On the one hand, this finding must be interpreted with
caution given that we only included hospitalized pa-
tients. On the other hand, this could be explained be-
cause we interviewed every patient or relative about the
presence of headache, reaching them by telephone if
necessary. We also extensively reviewed primary care
records, screening for the presence of headache. Further
studies will be necessary to clarify the real prevalence of
headache in COVID-19 patients, including outpatient
series.
Table 2 Predictors of mortality: univariate and multivariate logistic regression analysis
Type of analysis OR 95% CI p-value
mRS > 2 Univariate 11.371 6.376–20.278 < 0.001
Multivariate 3.714 1.880–7.338 < 0.001
Age Univariate 1.090 1.069–1.112 < 0.001
Multivariate 1.058 1.055–1.031 < 0.001
Female sex Univariate 0.682 0.454–1.024 0.065
Multivariate 0.703 0.413–1.196 0.194
Hypertension Univariate 3.534 2.272–5.495 < 0.001
Multivariate 1.379 0.802–2.370 0.245
Diabetes Univariate 2.129 1.353–3.351 0.001
Multivariate 1281 0.739–2.221 0.377
Smoking Univariate 1.589 1.004–2.514 0.048
Multivariate 1.907 0.997–3.275 0.051
Cardiological disorders Univariate 2.955 1.950–4.478 < 0.001
Multivariate 1.263 0.760–2.100 0.368
Pulmonary disorders Univariate 1.434 0.928–2.217 0.105
Multivariate 0.898 0.517–1.559 0.702
Cancer Univariate 1.641 1.001–2.690 0.049
Multivariate 1.254 0.694–2.266 0.453
Chronic neurological disorders Univariate 3.961 2.516–6.234 < 0.001
Multivariate 1.659 0.947–2.906 0.077
Immunosuppression Univariate 1.295 0.405–4.138 0.663
Headache Univariate 0.167 0.079–0.351 < 0.001
Multivariate 0.399 0.175–0.906 0.028
Time between onset of symptoms and ED visit Univariate 0.908 0.870–0.947 < 0.001
Multivariate 0.962 0.925–1.000 0.050
OR Odds Ratio, CI Confidence-interval, mRS Modified Rankin scale, ED Emergency department
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Table 3 Frequency of associated symptoms in the entire sample and the comparison between patients with and without headache
Variable All patients (n = 576) Headache (n = 137) No Headache (n = 439) Adjusted p-value
Anosmia 146 (25.3%) 64 (46.7%) 82 (18.7%) < 0.001
Arthralgia 35 (6.1%) 18 (13.1%) 17 (3.9%) < 0.001
Asthenia 242 (42.1%) 70 (51.1%) 172 (39.2%) 0.014
Chest pain 99 (17.2%) 33 (24.1%) 66 (15.1%) 0.015
Cough 403 (70.2%) 113 (82.5%) 290 (66.2%) < 0.001
Cutaneous rash 11 (1.9%) 4 (2.9%) 7 (1.6%) 0.322
Diarrhea 192 (33.4%) 54 (39.4%) 138 (31.4%) 0.084
Dyspnea 292 (50.8%) 73 (53.3%) 219 (49.9%) 0.487
Expectoration 90 (15.7%) 24 (17.5%) 66 (15.0%) 0.484
Fever 462 (80.3%) 121 (88.3%) 341 (77.7%) 0.006
Lightheadedness 60 (10.4%) 19 (13.9%) 41 (9.3%) 0.001
Myalgia 139 (24.1%) 55 (40.1%) 85 (19.1%) < 0.001
Odynophagia 60 (10.4%) 22 (16.1%) 38 (9.7%) 0.892
Rhinorrhea 12 (2.1%) 2 (1.5%) 10 (2.3%) 0.558
Syncope 43 (7.5%) 9 (6.6%) 34 (7.7%) 0.648
Vomiting 47 (8.2%) 11 (8%) 136 (8.2%) 0.949
Weakness 90 (15.7%) 26 (19.0%) 64 (14.6%) 0.216
In bold, variables that were statistically significant after adjusting for multiple comparisons (threshold p < 0.0029)









Leukocytes at admission 6710 (4945–8885.00) 6290.00 (4682.50–8257.50) 6785.00 (5137.50–9302.50) 0.202
Worst leukocyte count 9425.00 (4442.50–14,182.50) 6245.00 (3875.00–11,422.50) 9975.00 (4722.50–14,625.00) < 0.001
Lymphocytes at admission 990.00 (710.00–1387.50) 1117.00 (850.00–1495.00) 940.00 (680.00–1350.00) 0.003
Worst lymphocyte count 690.00 (430.00–1050.00) 910.00 (575.00–1220.00) 650.00 (410.00–990.00) 0.001
Platelets at admission 195,000.00 (156,000.00–257,000.00) 197,500.00 (170,500.00–240,750.00) 194,000.00 (149,000.00–264,000.00) 0.677
Worst platelet count 192,500.00 (137,000.00–341,250.00) 206,000.00 (163,000.00–384,500.00) 188,000.00 (134,000.00–333,500.00) 0.111
LDH at admission 285.00 (225.00–372.00) 263.00 (215.00–341.00) 292.50 (227.00–381.50) 0.019
Worst LDH value 285.00 (225.00–372.00) 301.50 (237.00–411.75) 365.00 (268.50–487.00) < 0.001
CK at admission 83.00 (49.00–372.00) 72.00 (49.5–110) 86.00 (47.00–166.00) 0.605
Worst CK value 89.00 (53.25–179.75) 79.00 (49.00–136.00) 94.00 (55.50–192.00) 0.026
CRP at admission 65.90 (23.37–122.15) 40.55 (14.15–102.26) 73.40 (28.55–130.05) 0.002
Worst CRP value 105.00 (51.25–198.02) 67.90 (21.70–164.40) 113.40 (58.45–208.62) < 0.001
PCT at admission 0.10 (0.06–0.26) 0.07 (0.04–0.14) 0.11 (0.07–0.30) 0.001
Worst PCT value 0.13 (0.06–0.43) 0.07 (0.04–0.18) 0.15 (0.08–0.54) < 0.001
Worst ferritin value 979.00 (444.40–1819.00) 615.00 (306.80–1449.70) 1094.80 (534.75–1945.47) < 0.001
Worst IL-6 value 27.80 (12.40–61.87) 17.95 (9.76–44.15) 33.50 (13.32–67.30) 0.001
D-Dimer at admission 761.50 (462.75–1369.00) 550.00 (380–864) 855.50 (515–50-1570.00) 0.001
Worst D-Dimer value 1300.00 (674.75–3231.75) 810.00 (504.50 (1458.50) 1534.00 (795.00–3580.00) < 0.001
INR at admission 1.18 (1.10–1.29) 1.15 (1.08–1.23) 1.19 (1.11–1.32) 0.003
Worst INR value 1.25 (1.15–1.40) 1.19 (1.11–1.30) 1.26 (1.17–1.45) < 0.001
LDH Lactate dehydrogenase, CK Creatine Kinase, CRP C-reactive protein, PCT Procalcitonin, IL-6 interleukin 6, INR International normalized ratio. In bold, variables
that were statistically significant after adjusting for multiple comparisons (threshold p < 0.0025)
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Table 5 Multivariate regression analysis of variables that were associated with the presence of headache
Variable OR 95% CI p-value Corrected p-value (Benjamini-Hochberg)
Presence of anosmia 2.306 1.449–4.247 < 0.001 0.001
Presence of myalgia 2.114 1.308–3.418 0.002 0.011
Age 0.976 0.959–0.993 0.005 0.018
Female sex 1.861 1.186–2.921 0.007 0.019
Rankin 0.654 0.455–0.940 0.022 0.048
Increased CRP on admission 0.451 0.227–0.897 0.023 0.042
Abnormal platelets on admission 0.516 0.291–0.912 0.023 0.036
Lymphopenia on admission 0.59 0.368–0.945 0.028 0.031
Presence of fever 2.105 1.043–4.247 0.038 0.046
Increased D-dimer on admission 0.616 0.388–0.978 0.04 0.044
Increased INR during hospitalization 0.627 0.384–1.024 0.062 0.062
In bold, variables that were statistically significant after adjusting for multiple comparisons (Benjamini-Hochberg procedure)
Fig. 1 Odds ratio and 95% confidence interval of variables associated with the presence of headache
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The main finding of our study was that headache was
associated with a lower probability of death. In our sam-
ple, headache patients had a different clinical picture, as
the frequency of symptoms such as anosmia, cough, my-
algia and arthralgia were higher. The higher frequency of
symptoms could suggest that those patients visited the
ED earlier; however, in our sample, patients with head-
ache presented to the ED later than those without head-
ache. This could reflect that patients without headache
suffer from a more severe case of COVID-19 and there-
fore they seek medical attention earlier [24].
Many laboratory results were also different in patients
with headache compared with the rest of the sample, al-
though these results should be interpreted cautiously
[25]. Headache patients were younger, more frequently
female, less disabled, and had lower frequencies of
hypertension, smoking habits, cardiac disorders, and
chronic neurological disorders. All of those could influ-
ence the crude results [3, 4], and therefore we did a
multivariate regression analysis to assess which variables
were independently associated with the presence of
headache.
The baseline factors that independently increased the
odds of having headache were the female sex, younger
age, and lower disability level at the baseline. These vari-
ables have been associated with a lower risk of death
from COVID-19 [4, 26]. However, in our study, head-
ache was independently associated with a lower risk of
death in the multivariate model.
Some symptoms were associated with higher odds of
headache, such as fever, anosmia and myalgia [27].
Fever, myalgia and headache are common in other sys-
temic viral infections [28–30]. These symptoms can be
related to lymphocyte and macrophage activation, inter-
feron secretion and cytokine release [31, 32]. An efficient
innate immunity response is associated with a better
COVID-19 prognosis. However, in some patients, the
immune response persists and causes endothelial dys-
function, thrombosis, persistent macrophage activation,
fibrinoid organizing pneumonia, acute respiratory dis-
tress syndrome, multi-organ failure and death [33].
Laboratory biomarkers reportedly associated with
COVID-19 pathophysiology include lymphocytes, CRP,
D-dimer [34], PCT, troponins, ferritin, and IL-6, among
others [22, 35]. In our sample, most of them differed be-
tween patients with and without headache. In the multi-
variate analysis, patients with headache had lower odds
of having increased CRP, abnormal platelet values, lym-
phopenia and increased D-dimer at the ED visit, and
these are factors that are typically associated with the
cytokine storm described in COVID-19 patients [32, 36].
In our opinion, this could partially explain the lower risk
of death experienced by COVID-19 patients with head-
ache [36]. However, it was also an unexpected finding,
as we hypothesized that the presence of headache could
be partially explained by those factors. We could not ex-
plain the lower levels of CRP or IL-6 due to the use of
NSAIDs or steroids, as patients with headache received
them less frequently than the rest of the sample. The
specific causes of headache might be further studied via
imaging and systematic cerebrospinal fluid evaluation.
Our findings should be interpreted with caution. In a
previous prospective study that included 179 hospital-
ized COVID-19 patients with pneumonia, mortality was
higher in patients with headache (5/21 (23.8%)) than
those without headache (12/158 (7.6%)); however, it did
not remain statistically significant in the multivariate re-
gression analysis [37]. In a meta-analysis that included
19 studies (2874 patients) published between January 1,
2020 and February 21, 2020, presence of headache was
not associated with a worse prognosis [38]. We propose
that the impact of headache in COVID-19 prognosis
should be studied in deeper detail. Compared with other
symptoms, headache might have different phenotypes
and each presentation might have a different meaning
[39, 40]. We hypothesize that the impact of headache on
prognosis might be linked to the causes of headache
[41]. If the presence of headache represents a more ef-
fective immune response, then it could be related to a
lower mortality. In those cases in which the headache is
associated with systemic complications, the prognosis
might be worse. However, in our study, most of the pa-
tients reported the headache early in the course of the
disease, and therefore the precise significance of later or
different headache presentations should also be
analyzed.
This study has notable weaknesses. It was a single-
center study, so the results may not be applicable to
other centers or countries. In addition, the sample in-
cluded only hospitalized patients, which could limit the
generalizability of the results. Further multicentric stud-
ies with larger sample sizes and inclusion of non-
hospitalized patients will be necessary to evaluate our
hypothesis and to clarify whether the prevalence of
headache differs between admitted and non-admitted
patients, particularly in patients with prior headache his-
tory. Finally, our study was retrospective and the col-
lected data may not be complete; despite the extensive
search, the frequency of headache could be underre-
ported due to the lack of prospective and iterative evalu-
ation, the unavailability of some patients, and the fact
that in some cases we contacted the relatives instead of
the patients. Some variables may be associated with the
lower age and higher frequency of female sex seen in pa-
tients with headache, so direct comparisons should be
interpreted cautiously. We did not assess the impact on
prognosis of the different possible headache phenotypes.
We encourage other researchers to pool the data and
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create a larger series that could better clarify the role of
prior history of headache disorders in the prognosis and
phenotyping of headache in COVID-19.
Conclusion
Headache is a frequent symptom in patients with
COVID-19. The presence of headache is an independent
predictor of lower risk of mortality in COVID-19 hospi-
talized patients. Anosmia, myalgia, fever and female sex
were independent predictors of headache in hospitalized
COVID-19 patients, while lower age and lower baseline
disability, CRP, platelet value, lymphocyte count and D-
dimer values on admission were independently associ-
ated with the presence of headache.
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